Akebia Therapeutics
AKBA
75 hedge funds and large institutions have $30.9M invested in Akebia Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 32 reducing their positions, and 22 closing their positions.
926% more call options, than puts
Call options by funds: $400K | Put options by funds: $39K
87% more capital invested
Capital invested by funds: $16.5M → $30.9M (+$14.4M)
0.03% more ownership
Funds ownership: 28.39% → 28.41% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 90 → 75 (-15)
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
78% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Alerce Investment Management
Chicago,
Illinois
|
+$3.27M |
| 2 |
Jane Street
New York
|
+$161K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.2K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$19K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$18.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$670K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$609K |
| 3 |
BlackRock
New York
|
-$428K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$245K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$154K |
AKBA Hedge Fund Activity: Q4 2022 in Review
75 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2022, worth a combined $30.9M — up 87% from $16.5M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AKBA and 9 opened new positions — a net loss of 13 holders — while 32 trimmed existing stakes and 7 added.
The largest buyer was Alerce Investment Management, adding an estimated $3.27M. The largest seller was Millennium Management, cutting an estimated $670K.
- 75 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2022, down from 90 in Q3 2022.
- Funds reported $30.9M of Akebia Therapeutics stock for Q4 2022, up 87% quarter-over-quarter.
- 9 funds opened new Akebia Therapeutics positions in Q4 2022 and 22 closed out, a net change of -13 holders.
- The largest Akebia Therapeutics buyer in Q4 2022 was Alerce Investment Management, an estimated $3.27M added.
- The largest Akebia Therapeutics seller in Q4 2022 was Millennium Management, an estimated $670K sold.
Based on aggregated 13F filings for Q4 2022.